We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.

We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.

Listen to an interview with one of the patients treated in the ongoing CLS-sponsored study at Skåne University Hospital, in Lund, Sweden.

Since CLS´s laser ablation system for neurosurgery was cleared by the FDA in September last year development has progressed rapidly. But how does it actually work? We explain in this news post.

Today Skåne University Hospital (SUS) published a press release with the title “Laser surgery in a magnetic camera – new help for patients with brain tumors”. The PM provides an insight to the ongoing study using CLS products for laser surgery inside a MRI camera. The hospital writes that doctors now can treat patients with hard-to-reach brain tumors that medical care was previously unable to help. So far two patients with brain tumors have been successfully treated as part of the study.

Dr Eric Walser is an internationally recognized interventional radiologist with extensive clinical experience of using non-surgical ablation for the treatment of small tumors as an alternative to traditional surgery. Dr Eric Walser uses the TRANBERG® Thermal Therapy System to treat localized prostate cancer in clinical practice.

CLS today announced that the first patient has been safely treated in the clinical trial at Skåne University Hospital (SUS) aiming to evaluate MR-guided Laser Interstitial Thermal Therapy (MRg LITT) for glioblastoma ablation.

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

We are happy to announce that our Chief Technology Officer Cristina Pantaleone today has been awarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden.

We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.

CEO Dan J. Mogren introduces our support for Movember. This annual campaign is all about raising awareness around male health, and specifically around prostate cancer. It is one of the most common cancer forms among men, but more can be done to spread knowledge about the disease.

Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.

We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!

The first patient will shortly be treated with the CLS laser ablation system in a sponsored study at Skåne University Hospital. The Swedish medical journal Läkartidningen now reports from the hospital.

We are now in the final preparations for the Imperial Prostate Masterclass meeting in London taking place this week. This is a small meeting, but this is also where we well meet the leading specialists and KOLs in the field.

Under teckningsperioden i CLS emission av units, som pågår t o m den 6 september 2022, planerar vi en rad aktiviteter för att berätta om vår verksamhet. Idag publiceras t.ex. ett hemma-hos reportage från vårt kontor i Lund.

The CLS team is looking forward to showcasing our new product generation towards urologists and radiologists through a variety of activities during the coming autumn...

There is a lot going on at CLS and the future looks very exciting to us! In this newsletter, we are happy to share some company updates. Read more and subscribe for future updates!

CEO Dan J. Mogren is presenting CLS at Biostock Life Science spring summit 2022. Watch the full presentation here.

SVTs lokalnyheter sände i tisdags ett reportage från Skånes universitetssjukhus där patienter opereras inne i en magnetkamera. Så kommer det också gå till när Skånes universitetssjukhus inleder laserablationsbehandlingar av hjärntumörer - med CLS system.

CLS och Skånes Universitetssjukhus ser fram mot den kommande kliniska studie där CLS system för laserablation kommer utvärderas för behandling av patienter med tumörsjukdomen glioblastom.

CLS has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.

CLS Americas today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study.

CLS is looking forward to participating in the annual European Conference on Interventional Oncology (ECIO) 2022, April 24-27 in Vienna, Austria. The meeting is the world’s most comprehensive platform for education and knowledge exchange within interventional oncology with over 1 450 international delegates attending.

Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Radboud University Medical Center (Radboudumc) in Nijmegen in the Netherlands has obtained approval from its ethics committee for its Investigator Initiated Trial (IIT) to evaluate the safety and feasibility of magnetic resonance guided focused laser ablation (MRgFLA) as a focal therapy treatment for localized prostate cancer in low to intermediate risk patients, using the TRANBERG® Thermal Therapy System with Thermoguide™ Workstation.

CLS and Skåne University Hospital enter a clinical trial agreement to evaluate laser ablation in glioblastoma patients Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image guided laser ablation, announces that it has entered into an agreement with Skåne University Hospital to sponsor a clinical trial evaluating the safety and feasibility of […]

CLS updates the company brand and launches new website Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that the company is launching a new website to further strengthen communication with the company’s customers. The website is based on a new brand platform with clear messages about the benefits the company’s products offer […]